Michael Friedländer

Medicine · Health Sciences

102h-index62.8kcitations924works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(440), BRCA gene mutations in cancer(233), PARP inhibition in cancer therapy(208), Endometrial and Cervical Cancer Treatments(94), Cancer Genomics and Diagnostics(89)

Publications875 total

Dose-dependent neurotoxic chemotherapy and corneal nerve morphological changes
Clinical and Experimental Optometry·2026
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) study
Cancer Epidemiology·2025
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
Nature Communications·2025· 1 citedOpen Access
Dose-dependent corneal nerve morphological changes due to neurotoxic chemotherapy: an in vivo corneal confocal microscopy study
Contact Lens and Anterior Eye·2025
Supplementary Data S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Table S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Table S2 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Table S3 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S4 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Table S4 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S3 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S2 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S5 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S6 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Data S1 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Table S2 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Table S4 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
Supplementary Figure S4 from Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial
2025Open Access
page 1 of 44Next →

Frequent Co-authors

Amit M. Oza(12), Nicoletta Colombo(10), Jonathan A. Ledermann(10), Ignace Vergote(10), Anne Floquet(9), Clare L. Scott(9), Susana Banerjee(8), Philipp Harter(8), Giovanni Scambia(7), Elizabeth Lowe(7), Richard T. Penson(7), Sandro Pignata(7), Ana Oaknin(6), Gabe S. Sonke(6), Charlie Gourley(6), Carol Aghajanian(6), Ronnie Shapira‐Frommer(6), Alla Lisyanskaya(5), Ursula A. Matulonis(5), Tamar Safra(5)